Darolutamidi yhdessä ADT- ja sädehoidon kanssa vähensi 58 prosentilla syövän leviämisen tai kuoleman vaaraa potilailla, joilla on suuri eturauhassyövän uusiutumisen riski

Impact · against what's priced in

The positive phase 3 interim results for darolutamide in high-risk prostate cancer represent a material catalyst for Orion. The 58% reduction in risk of cancer spread or death provides a concrete basis for increasing peak sales expectations and the probability of successful regulatory filings.

ORION+0.80

No priced-in read yet